·
-%
GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
dpa-AFX Nachrichten für idorsia Pharmaceuticals
-
-
· -%GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds
-
· -%GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
-
· -%GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
-
· -%GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting
-
· -%GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting
-
· -%GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs
-
· -%GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires
-
· -%GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
-
· -%GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration
-
· -%GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration
-
· -%GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation
-
· -%GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
-
· -%GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
-
· -%GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
-
· -%GNW-Adhoc: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call
-
· -%GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan
-
· -%GNW-Adhoc: Idorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
-
· -%GNW-Adhoc: Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll
-
· -%GNW-Adhoc: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million
-
· -%GNW-Adhoc: Invitation to Idorsia's HY 2023 Financial Results webcast and conference call
-
· -%GNW-Adhoc: Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
-
· -%GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
-
· -%GNW-Adhoc: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202
-
· -%GNW-Adhoc: Idorsia has secured bridge financing in the amount of CHF 75 million
-
· -%GNW-Adhoc: Idorsia bringt QUVIVIQ (Daridorexant) in der Schweiz auf den Markt - Erstes Medikament seiner Klasse für Behandlungen chronischer Schlaflosigkeit, das sowohl die nächtlichen Symptome als auch die Leistungsfähigkeit am Tag verbessert
-
· -%GNW-Adhoc: Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million
-
· -%GNW-Adhoc: Idorsia announces a change to commercial leadership
-
· -%GNW-Adhoc: Idorsia hält ordentliche Generalversammlung ab
-
· -%GNW-Adhoc: Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia